CA1079634A - Antigenes fixes a la surface externe de microvesicules - Google Patents

Antigenes fixes a la surface externe de microvesicules

Info

Publication number: CA1079634A
Authority: CA; Canada
Prior art keywords: microvesicles; antigenic; lipid; process according; protein
Prior art date: 1975-09-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA262,165A

Other languages

English (en)

Inventor

June D. Almeida

David C. Edwards

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wellcome Foundation Ltd

Original Assignee

Wellcome Foundation Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-09-29

Filing date

1976-09-28

Publication date

1980-06-17

1976-09-28 Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd

1980-06-17 Application granted granted Critical

1980-06-17 Publication of CA1079634A publication Critical patent/CA1079634A/fr

Status Expired legal-status Critical Current

Links

102000036639 antigens Human genes 0.000 title description 6
108091007433 antigens Proteins 0.000 title description 6
239000000427 antigen Substances 0.000 title description 5
230000000890 antigenic effect Effects 0.000 claims abstract description 61
102000004169 proteins and genes Human genes 0.000 claims abstract description 46
108090000623 proteins and genes Proteins 0.000 claims abstract description 46
238000002360 preparation method Methods 0.000 claims abstract description 36
241000700605 Viruses Species 0.000 claims abstract description 21
239000000232 Lipid Bilayer Substances 0.000 claims abstract description 12
238000000034 method Methods 0.000 claims description 44
239000002502 liposome Substances 0.000 claims description 32
150000002632 lipids Chemical class 0.000 claims description 28
239000000203 mixture Substances 0.000 claims description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
239000000243 solution Substances 0.000 claims description 11
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 10
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
239000000787 lecithin Substances 0.000 claims description 10
229940067606 lecithin Drugs 0.000 claims description 10
235000010445 lecithin Nutrition 0.000 claims description 10
238000013019 agitation Methods 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 7
125000001165 hydrophobic group Chemical group 0.000 claims description 7
239000012736 aqueous medium Substances 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 6
235000012000 cholesterol Nutrition 0.000 claims description 5
238000000108 ultra-filtration Methods 0.000 claims description 5
239000002671 adjuvant Substances 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
241000712461 unidentified influenza virus Species 0.000 claims description 3
229910019142 PO4 Inorganic materials 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
239000007858 starting material Substances 0.000 claims 5
229940070376 protein Drugs 0.000 claims 2
239000008366 buffered solution Substances 0.000 claims 1
238000000527 sonication Methods 0.000 claims 1
244000052769 pathogen Species 0.000 abstract description 3
241000894006 Bacteria Species 0.000 abstract description 2
229960003983 diphtheria toxoid Drugs 0.000 description 18
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
239000002953 phosphate buffered saline Substances 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
230000035931 haemagglutination Effects 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
239000000463 material Substances 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
210000004072 lung Anatomy 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
206010013023 diphtheria Diseases 0.000 description 5
206010022000 influenza Diseases 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
229960005486 vaccine Drugs 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
238000003556 assay Methods 0.000 description 4
RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 4
229940093541 dicetylphosphate Drugs 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
229940067631 phospholipid Drugs 0.000 description 4
230000004044 response Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000001492 haemagglutinating effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
239000001103 potassium chloride Substances 0.000 description 3
235000011164 potassium chloride Nutrition 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
241000700198 Cavia Species 0.000 description 2
241000709661 Enterovirus Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003599 detergent Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
241000182988 Assa Species 0.000 description 1
241000711404 Avian avulavirus 1 Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241001500351 Influenzavirus A Species 0.000 description 1
241001500350 Influenzavirus B Species 0.000 description 1
241001500343 Influenzavirus C Species 0.000 description 1
241000726306 Irus Species 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
235000018734 Sambucus australis Nutrition 0.000 description 1
244000180577 Sambucus australis Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
-1 disodium hydrogen Chemical class 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000008344 egg yolk phospholipid Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
239000000568 immunological adjuvant Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000014571 nuts Nutrition 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dispersion Chemistry (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA262,165A 1975-09-29 1976-09-28 Antigenes fixes a la surface externe de microvesicules Expired CA1079634A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB39857/75A GB1564500A (en)	1975-09-29	1975-09-29	Biological preparations

Publications (1)

Publication Number	Publication Date
CA1079634A true CA1079634A (fr)	1980-06-17

Family

ID=10411873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA262,165A Expired CA1079634A (fr)	1975-09-29	1976-09-28	Antigenes fixes a la surface externe de microvesicules

Country Status (15)

Country	Link
JP (1)	JPS5244228A (fr)
AU (1)	AU514848B2 (fr)
BE (1)	BE846681A (fr)
BG (1)	BG34181A3 (fr)
CA (1)	CA1079634A (fr)
DD (1)	DD127598A5 (fr)
DE (1)	DE2643641A1 (fr)
ES (1)	ES451923A1 (fr)
FR (1)	FR2325387A1 (fr)
GB (1)	GB1564500A (fr)
HU (1)	HU176180B (fr)
NL (1)	NL7610736A (fr)
PL (1)	PL103082B1 (fr)
SE (1)	SE7610708L (fr)
ZA (1)	ZA765817B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196191A (en)	1975-09-29	1980-04-01	Burroughs Wellcome Co.	Biological preparations
US4148876A (en)	1975-09-29	1979-04-10	Burroughs Wellcome Co.	Biological preparations
FR2420545A1 (fr) *	1978-03-20	1979-10-19	Anvar	Nouveaux esters de l'acide n-acetyl-muramyl-aminoacyl-glutamique ou des derives de substitution de celui-ci a proprietes anti-infectieuses et/ou d'adjuvants immunologiques
FR2442241A2 (fr) *	1978-03-20	1980-06-20	Anvar	Nouveaux composes esters de muramyl-peptide, leur preparation et les compositions pharmaceutiques les contenant, notamment sous forme de liposomes
GB2026340B (en) *	1978-07-03	1982-12-22	Ash P	Stabilising microvesicles
US4201767A (en)	1978-11-08	1980-05-06	Merck & Co., Inc.	Viral liposome particle
US4199565A (en)	1979-03-26	1980-04-22	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
HU184141B (en) *	1979-12-27	1984-07-30	Human Oltoanyagtermelo	Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
DE3173713D1 (en) *	1980-09-05	1986-03-20	Frappier Armand Inst	Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
FR2543018B1 (fr) *	1983-03-22	1985-07-26	Oreal	Procede de preparation de vesicules lipidiques par vaporisation de solvants
IT1238343B (it) *	1989-10-16	1993-07-13	Cesalpino Andrea Fond	Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
CA2131442A1 (fr) *	1992-03-03	1993-09-04	Seishi Tsuchiya	Vaccin oral
US6096291A (en) *	1996-12-27	2000-08-01	Biovector Therapeutics, S.A.	Mucosal administration of substances to mammals
US20160317646A1 (en) *	2013-12-19	2016-11-03	Crucell Holland B.V.	Formulations for virosomes

1975
- 1975-09-29 GB GB39857/75A patent/GB1564500A/en not_active Expired
1976
- 1976-09-28 JP JP51116473A patent/JPS5244228A/ja active Pending
- 1976-09-28 SE SE7610708A patent/SE7610708L/ not_active Application Discontinuation
- 1976-09-28 PL PL1976192701A patent/PL103082B1/pl unknown
- 1976-09-28 ZA ZA00765817A patent/ZA765817B/xx unknown
- 1976-09-28 FR FR7629064A patent/FR2325387A1/fr active Granted
- 1976-09-28 AU AU18164/76A patent/AU514848B2/en not_active Expired
- 1976-09-28 ES ES451923A patent/ES451923A1/es not_active Expired
- 1976-09-28 HU HU76WE542A patent/HU176180B/hu unknown
- 1976-09-28 NL NL7610736A patent/NL7610736A/xx not_active Application Discontinuation
- 1976-09-28 BE BE171023A patent/BE846681A/fr not_active IP Right Cessation
- 1976-09-28 BG BG034303A patent/BG34181A3/xx unknown
- 1976-09-28 DE DE19762643641 patent/DE2643641A1/de not_active Withdrawn
- 1976-09-28 CA CA262,165A patent/CA1079634A/fr not_active Expired
- 1976-09-28 DD DD7600195018A patent/DD127598A5/xx unknown

Also Published As

Publication number	Publication date
FR2325387A1 (fr)	1977-04-22
JPS5244228A (en)	1977-04-07
NL7610736A (nl)	1977-03-31
DD127598A5 (de)	1977-10-05
SE7610708L (sv)	1977-03-30
AU1816476A (en)	1978-04-06
AU514848B2 (en)	1981-03-05
FR2325387B1 (fr)	1980-06-27
HU176180B (en)	1980-12-28
ES451923A1 (es)	1977-08-16
DE2643641A1 (de)	1977-04-14
BG34181A3 (en)	1983-07-15
ZA765817B (en)	1978-05-30
BE846681A (fr)	1977-03-28
PL103082B1 (pl)	1979-05-31
GB1564500A (en)	1980-04-10

Legal Events

Date	Code	Title	Description
1997-06-17	MKEX	Expiry

Publication	Publication Date	Title
US4196191A (en)	1980-04-01	Biological preparations
US4148876A (en)	1979-04-10	Biological preparations
Perrin et al.	1985	Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre-and post-exposure protection studies
AU631377B2 (en)	1992-11-26	Affinity associated vaccine
CA2086831C (fr)	1999-03-16	Virosomes de la grippe reconstitues par immunostimulation et immunopotentialisation et vaccins contenant ceux-ci
Morein et al.	1985	Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes
JP3923518B2 (ja)	2007-06-06	ワクチン組成物用アジュバント
CA1079634A (fr)	1980-06-17	Antigenes fixes a la surface externe de microvesicules
US5643574A (en)	1997-07-01	Protein- or peptide-cochleate vaccines and methods of immunizing using the same
EP0440742A1 (fr)	1991-08-14	Immunoadjuvants liposomiques contenant de l'il-2.
JP2012532200A (ja)	2012-12-13	小胞を調製する方法及びこれから製造される製剤
EP0356340B1 (fr)	1994-11-02	Vaccin à affinité associée
US5897873A (en)	1999-04-27	Affinity associated vaccine
KR20170016315A (ko)	2017-02-13	알루미늄 염-흡착 백신의 면역자극 효력의 증진 방법
Kramp et al.	1979	Liposomal enhancement of the immunogenicity of adenovirus type 5 hexon and fiber vaccines
Boudreault et al.	1985	Mouse response to influenza immunosomes
JP3396478B2 (ja)	2003-04-14	ワクチン
Gregoriadis et al.	1992	Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen
Jolivet et al.	1981	Biological studies of lipophilic MDP-derivatives incorporated in liposomes
CN117618548A (zh)	2024-03-01	一种rsv疫苗组合物及其制备方法和应用
WO1990001947A1 (fr)	1990-03-08	Vaccin a affinite associee
WO2000076476A1 (fr)	2000-12-21	Liposomes polymerises a base d'adjuvant pour vaccination par voie orale, muqueuse ou intranasale
CA1334165C (fr)	1995-01-31	Vaccin avec antigenes associes par affinite
KR20220135935A (ko)	2022-10-07	제형화된 모노포스포릴 지질 a를 포함하는 면역증강용 조성물 및 그의 제조방법
Berezin et al.	1985	Isolation and studies of myxovirus glycoproteins